ABIOのチャート
ABIOの企業情報
| symbol | ABIO |
|---|---|
| 会社名 | ARCA biopharma Inc. （ARCAバイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 エーアルシーエー・バイオファマ（ARCA biopharma Inc.）は主に心不全及びその他心臓血管疾患のための遺伝子をターゲットにした治療法の開発に従事するバイオ医薬品企業。同社の主要候補製品の「Gencaro TM（ブシンドロール塩酸塩）」は、慢性心不全（HF）治療のために開発されている薬理学的特性を持つβ［ベータ］遮断薬及び血管拡張剤である。同社はLabCorp社と提携して、「Gencaro」に対する臨床反応を予測できる遺伝子マーカーのためのコンパニオン・テストであるGencaroテストを行っていた。同社の候補製品は「Gencaro（ブシンドロール塩酸塩）」は、慢性心不全（HF）治療のために開発されている薬理学的特性を持つβ［ベータ］遮断薬及び血管拡張剤である。「Gencaro」は心臓神経系においてβ-1とβ-2両方の受容体を遮断する性質を持っているため、β遮断薬クラスの化合物の一部として見なされる。これらの受容体の遮断を通して、「Gencaro」はこれらの受容体を活性化する用のその他分子との結合を防ぐ。 ARCAバイオファ―マは、米国のバイオ医薬品企業。心血管疾患の遺伝的標的治療の開発を中心に事業を展開。主要製品候補として、心不全および左心室機能障害の患者向けに心房細動治療のためのβ遮断薬、および軽度の血管拡張剤であるGencaro（ブシンドロ―ル塩酸塩）の開発を手掛ける。 ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO. |
| 本社所在地 | 11080 CirclePoint Road Suite 140 Westminster CO 80020 USA |
| 代表者氏名 | Robert E. Conway ロバート・E・コンウェイ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 720-940-2200 |
| 設立年月日 | 33817 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 14人 |
| url | http://arcabio.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/abio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.67700 |
| 終値（lastsale） | 0.6301 |
| 時価総額（marketcap） | 8773402.1325 |
| 時価総額 | 時価総額（百万ドル） 8.61467 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.02033 |
| 当期純利益 | 当期純利益（百万ドル） -13.48100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Arca Biopharma Inc revenues was not reported. Net loss decreased 51% to $4.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.07 to -$0.35. |
ABIOのテクニカル分析
ABIOのニュース
ALBIOMA : Objectifs confirmés chez Albioma malgré du retard pour Le Moule 3 2020/08/03 06:00:00 Investir-Les Echos Bourse
Albioma : Availability of half-year financial report (first half of the 2020 financial year) (pdf) | MarketScreener 2020/07/30 15:51:33 MarketScreener
Press release Paris La Défense, 30 July 2020 Availability of Half-Year Financial Report … | July 30, 2020
Albioma : First-half 2020 results (pdf) | MarketScreener 2020/07/27 15:46:06 MarketScreener
Press release Paris La Défense, 27 July 2020 First-half 2020 results Strong rise in EBITDA and net income,… | July 27, 2020
ALBIOMA : La tendance est un alliée précieux 2020/06/25 07:00:00 BFM Bourse
https://www.tradingsat.com/albioma-FR0000060402/conseils/albioma-la-tendance-est-un-alliee-precieux-919831.html
Albioma : wins 2.9 MWp of solar projects in mainland France (pdf) | MarketScreener 2020/06/11 15:48:16 MarketScreener
Press release Paris La Défense, 11 June 2020 Albioma wins 2.9 MWp of solar projects in mainland France Albioma… | June 11, 2020
ALBIOMA : La tendance est un alliée précieux 2020/06/25 07:00:00 BFM Bourse
https://www.tradingsat.com/albioma-FR0000060402/conseils/albioma-la-tendance-est-un-alliee-precieux-919831.html
Albioma : wins 2.9 MWp of solar projects in mainland France (pdf) | MarketScreener 2020/06/11 15:48:16 MarketScreener
Press release Paris La Défense, 11 June 2020 Albioma wins 2.9 MWp of solar projects in mainland France Albioma… | June 11, 2020
The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight 2020/05/30 13:25:31 Benzinga
Biotech stocks could not sustain the uptrend in the holiday-shortened week, even as traders digested COVID-19-related news flow, clinical readouts, ASCO presentations and a few FDA approvals. Arca Biopharma Inc (NASDAQ: ABIO ) was the best performing biotech stock of the week, as it rallied in reaction to an announcement from the company regarding testing of its pipeline asset for COVID-19-associated coagulopathy. The week also saw Merck & Co., Inc. (NYSE: MRK ) taking a giant leap of faith into the COVID fray after remaining non-committal thus long. Here are the key catalysts for the unfolding week. Conferences Jefferies Virtual Healthcare Conference: June 2-4 European Academy of Allergy and Clinical Immunology, or EAACI, Digital Conference 2020: June 6-8 PDUFA Dates The FDA is set to rule on Menlo Therapeutics Inc's (NASDAQ: MNLO ) FMX103 - 1.5% minocycline foam -, which came into its stable via its Foamix acquisition, as a … Full story available on Benzinga.com
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant 2020/05/29 11:22:24 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO )( announced a collaboration study for razuprotafib in COVID-19 treatment) Aileron Therapeutics Inc (NASDAQ: ALRN ) Arca Biopharma Inc (NASDAQ: ABIO ) ( reacted to its planned foray into COVID-19 treatment) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) ChemoCentryx Inc (NASDAQ: CCXI ) GENMAB A/S/S ADR (NASDAQ: GMAB )(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) Imara Inc NASDAQ: (IMRA) Liquidia Technologies Inc (NASDAQ: LQDA ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Tenax Therapeutics Inc (NASDAQ: TENX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Vermillion, Inc. (NASDAQ: VRML ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 28) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Karyopharm to Present Positive Selinexor Data In Multiple Myeloma Patients At ASCO Karyopharm Therapeutics Inc (NASDAQ: KPTI ) announced detailed results from the pivotal Phase 3 BOSTON study that evaluated once-weekly selinexor in combination with once-weekly Velcade and low-dose dexamethasone, or SVd, compared to the standard twice-weekly Velcade plus low-dose dexamethasone, or Vd, in second-line to fourth-line setting in multiple myeloma patients.
Arca Biopharma’s stock nearly quadruples on COVID treatment news 2020/05/29 00:42:34 Daily Camera
Arca Biopharma Inc. became the latest darling among health-care stocks Thursday after saying one of its drug candidates is showing promise as a treatment for blood clotting seen in some COVID-19 patients.
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company 2020/03/20 11:44:59 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection 2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings 2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
Point recommandation des analystes : Schneider, Edenred, Safran, Albioma, Total... 2020/03/04 07:06:29 BFM Bourse
https://www.tradingsat.com/actualites/avis-brokers/point-recommandation-des-analystes-schneider-edenred-safran-albioma-total-902919.html
ALBIOMA : Les résultats d'Albioma dépassent les attentes 2020/03/03 15:12:00 Investir-Les Echos Bourse
Le spécialiste de la production d'énergie renouvelable a publié un chiffre d'affaires et un résultat net supérieurs aux anticipations. Le groupe affiche des objectifs ambitieux pour l'exercice en cours.